



Viral Vectors & Vaccines – Program Chairs:

Otto-Wilhelm Merten, PhD • Généthon
Amine A. Kamen, PhD • McGill University

Cellular Therapies – Program Chairs:

Martin A. Giedlin, PhD • Poseida Therapeutics, Inc.
Gary K. Lee, PhD • Sangamo Therapeutics, Inc.

Baculovirus Expression Technology – Program Chairs:

Manuel J.T. Carrondo, PhD • Instituto de Biologia Experimental e Tecnológica (iBET)
Clifton E. McPherson, PhD • Protein Sciences Corporation, A Sanofi Company

SUNDAY - MARCH 4, 2018

3:00 pm – 7:00 pm

Welcome Reception and Registration in the Granby Ballroom Foyer, Third Floor

MONDAY - MARCH 5, 2018

7:00 am – 8:00 am

Registration and Breakfast in the Granby Ballroom Foyer, Third Floor

8:00 am – 8:30 am

Meeting Overview in Momentum, Third Floor

	Viral Vectors & Vaccines Momentum, Third Floor View Speaker Abstracts & Bios	Cellular Therapies Fusion, Third Floor View Speaker Abstracts & Bios	Baculovirus Expression Technology Energy, Third Floor View Speaker Abstracts & Bios
8:30 am – 9:15 am	<i>OneBac rAAV Scale-Up Production Platform with Serotype-Specific Modulation of AAV Capsid Protein Stoichiometry</i> Sergei Zolotukhin, PhD University of Florida	<i>Successful Manufacturing of T-Cell Therapies: Challenges and Opportunities</i> Cenk Sumen, PhD Hitachi Chemical Advanced Therapeutics Solutions, LLC	<i>The Complete Genome Sequences of Two Trichoplusia ni Cell Lines</i> Dominic Esposito, PhD Frederick National Laboratory for Cancer Research and Yu Fu University of Massachusetts Medical School
9:15 am – 10:00 am	<i>Biological Activity of Additional AAV Subpopulation in AAV Gene Therapy Product</i> Marian Bendik Shire	<i>Cell Therapy: Islet Isolation and Transplant Quality Control Release Considerations</i> Lisa Stehno-Bittel, PhD Likarda, LLC	<i>Cervarix Vaccine: From Baculovirus Technology to the First Human BEVS-Based Vaccine</i> Isabelle Knott, PhD GlaxoSmithKline Biologicals
10:00 am – 10:30 am	Morning Break in the Exhibit Area		
10:30 am – 11:00 am	Technology Workshop <i>Consideration for Biosafety Testing of Viral Vectors and Vaccines</i> SGS Vitrology	Technology Workshop <i>Design of Experiments and Multivariate Data Analysis in the Future of Cell Therapy and Regenerative Medicine</i> Sartorius Stedim North America Inc.	Technology Workshop <i>A Chemically-Defined Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells</i> Thermo Fisher Scientific
11:00 am – 11:30 am	Technology Workshop <i>Scaling Up and Industrializing the Production of Viral Vectors and Cells for Therapeutic Use</i> Pall Life Sciences	Technology Workshop Lonza	Technology Workshop <i>Laser Force Cytology: A Novel Technology for Rapid Quantification of Viral Infectivity and Label-Free Cellular Analysis</i> LumaCyte
11:30 am – 12:00 noon	Technology Workshop <i>Optimized Quantification Methods to Determine the Portion of Full AAV Capsids and Avoid Empty and Disrupted Particles</i> Vironova AB	Technology Workshop <i>Gibco™ LV-MAX™ Lentiviral Production System for Cell Therapy Applications</i> Thermo Fisher Scientific	Technology Workshop Pending
12:00 noon – 1:30 pm	Lunch in the Exhibit Area (Poster Session from 1:00 – 1:30 pm)		
1:30 pm – 2:15 pm	<i>The Development and Intensification of a Lentiviral Vector Manufacturing Process Using Stable Cell Lines</i> Lesley Chan, PhD bluebird bio Inc.	<i>CAR T-Cells with Non-Viral Gene-Editing Technology</i> David L. Hermanson Poseida Therapeutics, Inc.	<i>Towards Routine Manufacturing of Gene Therapy Drugs – Requirements for Further Improvements – Example: AAV</i> Otto-Wilhelm Merten, PhD Généthon
2:15 pm – 3:00 pm	<i>Viral Vector Manufacturing: Challenges and Solutions</i> Hanna P. Lesch, PhD FinVector Vision Therapies OY	<i>Enhancing CAR T-Cell Specificity for Malignancy and Maintaining Durable Persistence in Solid Tumor Models</i> Avery D. Posey Jr., PhD University of Pennsylvania	<i>Enabling Access to a Norovirus Virus-Like Particle-Based Vaccine Through Advanced Manufacturing Process Design</i> Scot Shepard Takeda Pharmaceuticals U.S.A., Inc.
3:00 pm – 3:30 pm	Afternoon Break in the Exhibit Area		
3:30 pm – 4:15 pm	<i>Characterization of Stability-Indicating Assays for Viral Vectors</i> Lawrence C. Thompson, PhD Pfizer, Inc.	<i>Metabolomics: Enabling Understanding and Optimization of Bioprocesses and Immunotherapies</i> Kendra Hightower, PhD Metabolon, Inc.	<i>Bioprocess Engineering of Insect Cells for Pseudotyped VLP Expression and Optimization</i> António M. Roldao, PhD Instituto de Biologia Experimental e Tecnológica
4:15 pm – 5:00 pm	<i>Analytical Strategies on Quantification of Adeno-Associated Virus (AAV) Empty Capsids to Support Process Development</i> Xiaohui Lu, PhD Biogen	<i>Achieving High Quality Cell-Based Measurement: Application to Process Controls and Potency Assays</i> John T. Elliott National Institute of Standards & Technology	<i>Tweaking Baculovirus Expression Vectors to Stabilize Transgenes and Polish Enveloped VLP Vaccines</i> Gorben P. Pijlman, PhD Wageningen University

5:00 pm – 6:00 pm

Plenary Session in Momentum, Third Floor: **Air Handling for Viral Vector Suites**
Christian D. Lynch • FDA CBER, **Mark F. Witcher, PhD** • NNE, and **Kim L. Nelson, PhD** • CRB

6:00 pm – 8:00 pm

Reception in the Exhibit Area

	Viral Vectors & Vaccines Momentum, Third Floor	Cellular Therapies Fusion, Third Floor	Baculovirus Expression Technology Energy, Third Floor
7:30 am – 8:30 am	Breakfast in the Exhibit Area		
8:30 am – 9:15 am	<i>Analytical Issues for AAV Gene Therapy Products: Vector Genome Titration and Full/Empty Viral Particles Quantification</i> Christine Le Bec, PhD Généthon	<i>High Throughput Identification of Naturally-Occurring T-Cell Receptors with Therapeutic Potential Against Tumor-Associated, Viral, and Neoantigens</i> Adria Carbo, PhD Adaptive Biotechnologies	<i>Simplifying Membrane Protein Purification: Introducing a Fluorescent BEVS Protein System that Enhances Protein Production and Greatly Simplifies Detergent Screening</i> Kendra Steele, PhD ParaTechs Corporation
9:15 am – 10:00 am	<i>Many Ways Lead to Rome for Assessing the Genetic Stability of a Viral Vector</i> Pepijn Burgers, PhD Janssen Vaccines & Prevention B.V.	<i>Improving the Preservation of T-Cells</i> Chia-Hsing Pi University of Minnesota	<i>Adventitious Viruses Contaminating Insect Cell Lines</i> Christoph Geisler, PhD GlycoBac LLC
10:00 am – 10:30 am	Morning Break in the Exhibit Area		
10:30 am – 11:15 am	<i>Novel Purification Process to Obtain Pure AAV Vectors of 1e+16 vg in a Single Run of Conventional Ultracentrifuge</i> Haifeng Chen, PhD Virovek, Inc.	<i>T-Cell Activation Co-Stimulatory Ligands on a Dissolvable Substrate to Modulate T-Cell Output</i> Sean H. Kevlahan, PhD Quad Technologies	<i>Regulatory Updates and Using Virus-Like Particles to Inform Norovirus Vaccine Design</i> Robin Levis, PhD and Gabriel I. Parra, PhD FDA CBER
11:15 am – 12:00 noon	<i>Scalable Lentiviral Vector Production Using Stable HEK293 Suspension Cells</i> Aziza P. Manceur, PhD National Research Council Canada	Sunetra Biswas, PhD Kite, A Gilead Company	<i>Comparative Transcriptome Analysis of AcMNPV Infection in the Midgut of Host Insect <i>Trichoplusia ni</i>, and in a <i>T. ni</i> Cell Line</i> Gary W. Blissard, PhD Boyce Thompson Institute
12:00 noon – 12:45 pm	<i>Testing Approaches for Viral Vectors Used in Gene Therapy: Novel Methods and Regulatory Expectations</i> Leyla Diaz, PhD MilliporeSigma BioReliance® Services	Lentivirus Reference Standard Working Group Meeting in Energy, Third Floor Free Afternoon with Recommended Group Activities: River Cruise on the Victory Rover • Admission to Nauticus and the Battleship Wisconsin • Historical Walking Tour Psychedelic Banquet at Half Moone featuring BJ Griffin & the Galaxy Groove	
12:45 pm – 2:00 pm			
2:00 pm – 2:45 pm			
2:45 pm – 6:00 pm			
6:00 pm – 9:00 pm			

WEDNESDAY - MARCH 7, 2018

	Breakfast in the Exhibit Area		
7:30 am – 8:30 am			
8:30 am – 9:15 am	<i>Challenges in Process Development and Industrialization for Live Virus Vaccine: Flavivirus Experience Using a Vero Cell Line</i> Etienne Boutry Sanofi Pasteur SA	<i>Chemically-Defined Culture Media for Advancing Cell Therapy Technology</i> Jessie H.T. Ni, PhD Irvine Scientific	<i>Control Using BEVS: From Promoters to CRISPR</i> Marc G. Aucoin, PhD University of Waterloo
9:15 am – 10:00 am	<i>Large-Scale Manufacturing of Clinical-Grade rAAV in an Academic Setting: How Efficacy, Versatility, Space, and Cost Drive Process and Development Toward Sustainable Methods</i> Nathalie A. Clément, PhD University of Florida	<i>The Role of Leukapheresis and Elutriation in Cell Immunotherapy Manufacturing</i> Joseph M. Roig Terumo BCT	<i>HER2 Cancer Vaccine Optimization by Combining Drosophila S2 Insect Cell Manufacturing with a Novel VLP-Display Technology</i> Willem "Wian" A. de Jongh, PhD ExpreS2ion Biotechnologies
10:00 am – 10:30 am	Morning Break in the Exhibit Area		
10:30 am – 11:15 am	<i>Novel Stable Lentiviral Vector Producer Cells: Overcoming Viral Vector Cytotoxicity</i> Ana Sofia Coroadinha, PhD Instituto de Biologia Experimental e Tecnológica	<i>Engineered Pluripotent Cell-Derived NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy</i> Bahram "Bob" Valamehr, PhD Fate Therapeutics, Inc.	<i>Progress on the Genome of the Spodoptera frugiperda Sf9 Cell Line</i> Arifa S. Khan, PhD FDA CBER
11:15 am – 12:00 noon	<i>Retroviral and Lentiviral Production in Disposable Bioreactor: Development and Scaling Up of Upstream and Downstream Process Steps</i> Francesca Bellintani MolMed S.p.A.	<i>Optimizing the CAR T-Cell Supply Chain</i> Kimberly Lounds-Foster Celgene Corporation	<i>rAAV Vector Development and Large-Scale Manufacturing Using BEVS Technology</i> Jacek Lubelski, PhD uniQure N.V.
12:00 noon – 1:30 pm	Lunch in the Exhibit Area (Poster Session from 1:00 – 1:30 pm)		
1:30 pm – 2:15 pm	<i>The Use of Automation in the Development of Lentiviral Vector Packaging and Producer Cell Lines</i> Helen Maunder, PhD Oxford BioMedica plc	<i>Automated, Closed System Manufacturing of CAR T-Cells</i> Philip Coelho Thermogenesis Corp.	<i>PEI-Mediated Transient Transfection of Insect Cells for the Expression of Recombinant Proteins in Stirred-Tank Bioreactors</i> Christopher W. Kemp, PhD Kempbio, Inc.
2:15 pm – 3:00 pm	<i>CAP-GT, a Platform Addressing the Production Challenge</i> Nicole Faust, PhD Cevec Pharmaceuticals GmbH	<i>Regulatory Approval of Modern Gene-Based Cancer Immunotherapies — CAR T-Cells — A Product Perspective</i> Xiaobin "Victor" Lu, PhD FDA CBER	<i>Biochemical and Biophysical Characterization of Adeno-Associated Viruses Produced by Triple Transfection in HEK293 Cells and with Insect Cells/Baculovirus Expression System</i> Eric Horowitz, PhD Voyager Therapeutics
3:00 pm – 3:30 pm	Afternoon Break in the Exhibit Area		
3:30 pm – 4:15 pm	<i>Pushing the Boundaries of Adeno-Associated Virus Characterization for Enhanced Product and Process Understanding</i> Thomas Wesley Powers Pfizer, Inc.	<i>Integrated, Closed System PAT Analytics for Advanced Auto Feedback Control of Critical Process Parameters — Reactive Analytics</i> Dan Kopec Sartorius Stedim Biotech	Jamal Meghrouh Protein Sciences Corporation, A Sanofi Company
4:15 pm – 5:00 pm	<i>A Suspension Vero Cell Line for Production of Viral Vaccines and Viral Therapeutics</i> Steven E. Pincus, PhD FUJIFILM Diosynth Biotechnologies Texas, LLC	<i>Tumor Infiltrating Lymphocytes: Streamlining Manufacturing for Multi-Center Clinical Trials and Commercialization</i> Linda L. Kelley, PhD H. Lee Moffitt Cancer Center & Research Institute	<i>HepE Viral Nanoparticle (HEVNP): A Multifunctional Platform for Oral Delivery</i> Chun C. Chen, PhD Astrid Pharma
5:00 pm	Meeting Adjourns		